[Previous Months][Date Index][Thread Index][Join - Register][Login]
  [Message Prev][Message Next][Thread Prev][Thread Next]

[IP] Weight in adolescents with type 1 during CSII

J Pediatr Endocrinol Metab 2002 May;15(5):607-12     <A HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12014519&dopt=Abstract">Entrez-PubMed</A> 

Weight in adolescents with type 1 diabetes mellitus during continuous 
subcutaneous insulin infusion (CSII) therapy.

Raile K, Noelle V, Landgraf R, Schwarz HP.

Division of Endocrinology and Diabetes, Children's Hospital, 
Ludwig-Maximilians-University of Munich, Germany. email @ redacted

Continuous subcutaneous insulin infusion (CSII) has become increasingly 
popular as a form of intensified insulin therapy in adolescents with type 1 
diabetes mellitus (DM). One reported drawback was increased weight gain in 
adolescents after initiation of insulin pump therapy. In a prospective, 
longitudinal, non-randomized and case controlled study, we followed 12 
adolescents (mean age 13.6 yr, 8 males, 4 females) from 6 months before the 
start of CSII to 12 months on CSII. These 12 adolescents with DM on CSII were 
matched for age, gender, HbA1c, duration of DM, and body mass index (BMI) 
with 12 adolescents who continued on multiple injection therapy (MIT). In 
addition, six of the 12 adolescents on CSII intended to control their weight 
by means of the insulin pump. These six vs six adolescents within the CSII 
group were further analyzed for weight development and eating habits. 
Clinical indications for CSII were dawn phenomenon, night-time hypoglycemia 
and patient request for more flexibility in DM management. All patients had 
been in satisfactory metabolic control on MIT. After 12 months of CSII, the 
daily insulin requirement remained significantly lower than 18 months before 
(0.79 +/- 0.11 vs 1.02 +/- 27 U/kg/d, p = 0.034) and number of daily meals 
was lower (4.1 +/- 0.9 vs 6.5 +/- 0.7, p = 0.006). Mean initial HbA1c was 
7.4% in the MIT and CSII patients, and remained comparable between these two 
groups. BMI was not different between the CSII and MIT group over the entire 
study period. However, those adolescents on CSII who intended to control 
their weight by means of the insulin pump were able to achieve relative 
weight loss during the,first 6 months on CSII. Two patients of the CSII group 
had one severe hypoglycemic episode with loss of consciousness. In 
conclusion, CSII does not lead to weight gain by itself, but allows 
sufficient weight control without a negative effect on metabolic control. The 
general threat of weight gain in patients who switch to insulin pump therapy 
must be pointed out, and the role of eating habits and caloric content of 
food should play a central role in insulin pump educational programs.

PMID: 12014519 [PubMed - in process]    
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml